Our study employed an unbiased whole-genome approach to demonstrate that the JNK signalling cascade plays an important role in driving insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer. The gene discussed is CDK4; the disease is breast carcinoma.